相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers
Tadeusz Dyba et al.
EUROPEAN JOURNAL OF CANCER (2021)
CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity
Shigeaki Sunada et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
Timothy Johnson et al.
EBIOMEDICINE (2021)
Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges
Sumera Zaib et al.
BIOORGANIC CHEMISTRY (2020)
The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors
Xiu-Juan Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review
Jaiprakash Sangshetti et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
Saowaluk Saisomboon et al.
HELIYON (2019)
Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition
Daniel J. Wood et al.
CELL CHEMICAL BIOLOGY (2019)
Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors
Wei Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity
Kamilia M. Amin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl) phthalazine derivatives
Wagdy M. Eldehna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation
Sahar M. Abou-Seri et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro
Daniela Cihalova et al.
BIOCHEMICAL PHARMACOLOGY (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
Improvement of antibacterial activity of some sulfa drugs through linkage to certain phthalazin-1(2H)-one scaffolds
Hany S. Ibrahim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
The role of drug metabolizing enzymes in clearance
Li Di
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Synthesis and antitumor activities of novel 1,4-substituted phthalazine derivatives
Shu Lan Zhang et al.
CHINESE CHEMICAL LETTERS (2010)
CDK Inhibitors: From the Bench to Clinical Trials
Flavio Rizzolio et al.
CURRENT DRUG TARGETS (2010)
Synthesis and in vitro cytotoxicity of novel 1,4-disubstituted phthalazines
Xin Zhai et al.
CHINESE CHEMICAL LETTERS (2008)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
PF Hollenberg
DRUG METABOLISM REVIEWS (2002)
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
G Bold et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
